Author

Kui Wang

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study

Background To compare the efficacy and safety of combined locoregional and systemic therapy vs systemic therapy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Methods This multicenter retrospective study included 337 patients with HCC and PVTT who received systemic therap...

J. Liu, Yuxuan Lin, Kong-Ying Lin et al. · Journal of Hepatocellular Ca... · 0 citations

Open access Sep 2026

Integrating Magnetic Resonance Imaging-Based Deep Learning and Radiomics to Predict Treatment Response in Hepatocellular Carcinoma Receiving Combined Systemic and Locoregional Therapies: A Multicenter Study

Abstract Background Although combining systemic and locoregional therapies has improved outcomes for hepatocellular carcinoma (HCC), identifying appropriate candidates remains challenging because no reliable tool predicts response. Methods This retrospective multicenter study enrolled 334 HCC patients who received firs...

Lu-Na Wang, Shi-Qi Zhou, Fei Li et al. · Liver Cancer · 0 citations

Open access Sep 2026

Targeting TREM2+ and TIMD4+ Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma

TREM2+ and TIMD4+ macrophages are key regulators of the immunosuppressive TME in ICC, and combining anti-Trem2 and anti-Timd4 with anti-Pd-1 antibodies significantly improved treatment outcomes in the ICC mice.

Yao Li, Hong-Wen Liu, Lei Xu et al. · Cancer Communications · 0 citations

Clinical trial Aug 2026

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

BACKGROUND Resection might offer additional benefit in patients with advanced-stage hepatocellular carcinoma treated with systemic therapy. However, high-quality evidence supporting the procedure is absent. We aimed to establish whether resection can provide survival benefit in patients with advanced hepatocellular car...

Hui-Chuan Sun, Xiao-Dong Zhu, Feng Shen et al. · The Lancet · 3 citations · ⚡1